Genzyme's Alemtuzumab for Multiple Sclerosis Shows Durable Treatment Benefit in Review of Four-Year Phase 2 Trial Data

Genzyme Corporation (Nasdaq: GENZ) reported that four-year follow-up data from its completed Phase 2 multiple sclerosis (MS) trial continued to show durable reductions in relapse rate and sustained accumulation of disability three years after the majority of patients received their last course of the investigational compound alemtuzumab. The CAMMS223 Phase 2 trial compared alemtuzumab to an approved MS therapy Rebif® (interferon beta-1a) in early, relapsing-remitting multiple sclerosis (RRMS) patients who had received no prior therapy. The accumulated four-year efficacy and safety data from the Phase 2 trial will be presented today in Germany at the European Committee for Treatment...

Want to see the full article?

• Purchase this article for only $3.00